Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of Function.
Hauck PM, Wolf ER, Olivos DJ 3rd, Batuello CN, McElyea KC, McAtarsney CP, Cournoyer RM, Sandusky GE, Mayo LD. Hauck PM, et al. Among authors: sandusky ge. Mol Cancer Res. 2017 Nov;15(11):1598-1607. doi: 10.1158/1541-7786.MCR-17-0174. Epub 2017 Aug 7. Mol Cancer Res. 2017. PMID: 28784612 Free PMC article.
Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.
Tonsing-Carter E, Bailey BJ, Saadatzadeh MR, Ding J, Wang H, Sinn AL, Peterman KM, Spragins TK, Silver JM, Sprouse AA, Georgiadis TM, Gunter TZ, Long EC, Minto RE, Marchal CC, Batuello CN, Safa AR, Hanenberg H, Territo PR, Sandusky GE, Mayo LD, Eischen CM, Shannon HE, Pollok KE. Tonsing-Carter E, et al. Among authors: sandusky ge. Mol Cancer Ther. 2015 Dec;14(12):2850-63. doi: 10.1158/1535-7163.MCT-15-0237. Epub 2015 Oct 22. Mol Cancer Ther. 2015. PMID: 26494859 Free PMC article.
Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.
Arpin CC, Mac S, Jiang Y, Cheng H, Grimard M, Page BD, Kamocka MM, Haftchenary S, Su H, Ball DP, Rosa DA, Lai PS, Gómez-Biagi RF, Ali AM, Rana R, Hanenberg H, Kerman K, McElyea KC, Sandusky GE, Gunning PT, Fishel ML. Arpin CC, et al. Among authors: sandusky ge. Mol Cancer Ther. 2016 May;15(5):794-805. doi: 10.1158/1535-7163.MCT-15-0003. Epub 2016 Feb 12. Mol Cancer Ther. 2016. PMID: 26873728 Free PMC article.
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.
Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RL, Reed A, Turner SA, De Abreu FB, Gallagher T, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM. Hahn NM, et al. Among authors: sandusky ge. Clin Cancer Res. 2017 Jun 15;23(12):3003-3011. doi: 10.1158/1078-0432.CCR-16-2267. Epub 2016 Dec 8. Clin Cancer Res. 2017. PMID: 27932416 Free PMC article. Clinical Trial.
Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer.
Wang R, Bhat-Nakshatri P, Padua MB, Prasad MS, Anjanappa M, Jacobson M, Finnearty C, Sefcsik V, McElyea K, Redmond R, Sandusky G, Penthala N, Crooks PA, Liu J, Zimmers T, Nakshatri H. Wang R, et al. Mol Cancer Ther. 2017 Dec;16(12):2747-2758. doi: 10.1158/1535-7163.MCT-17-0717. Epub 2017 Oct 4. Mol Cancer Ther. 2017. PMID: 28978719 Free PMC article.
221 results